申请人:REGENTS OF THE UNIVERSITY OF MINNESOTA
公开号:US20160193305A1
公开(公告)日:2016-07-07
The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.
本发明涉及一种基于前药转化的新型药物输送策略,其中水溶性前药及其转化酶在给药点(如鼻黏膜或颊黏膜)同时输送。前药经酶促转化产生的药物浓度超过了药物的热力学溶解度或饱和水平。超饱和药物在结晶之前由于其高热力学活性迅速穿过黏膜膜。该策略在需要快速作用的情况下特别有用,例如在预防或迅速应对癫痫持续状态(SE)或其他中枢神经系统疾病(如偏头痛)时。